ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AMYT Amryt Pharma Plc

143.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 143.00 151.00 170.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Amryt Pharma Share Discussion Threads

Showing 6601 to 6625 of 7375 messages
Chat Pages: Latest  271  270  269  268  267  266  265  264  263  262  261  260  Older
DateSubjectAuthorDiscuss
06/5/2021
09:49
Some assurances here - my instinct tells me that Chiasma was a good purchase at $297 million USD. Octreotide has annual sales of over 1 billion USD; Lanreotide has annual sales of 1 billion Euro (or roughly 800 million USD). This revenue is coming from 2 main indications:- acromegaly and GEP-NET. Hence, I believe that an annual sales for Mycapssa (an oral octreotide) of 200 million USD is a realistic figure for Amryt, with higher targets if approval in GEP-NET is achieved. Currently, most acromegaly patients are receiving octreotide or lanreotide injections once-monthly, and I believe that a proportion of patients would welcome the option of oral dosing.
diamondstar1
06/5/2021
09:30
Bought a few more. Buy when theres blood on the streets
volsung
06/5/2021
07:27
Currently 3rd biggest percentage faller according to advfn.
papillon
06/5/2021
07:09
I'm thanking my lucky stars I only kept 500 AMYT shares after selling most yesterday at circa £2.The share price has opened up well down this morning in line with the Nasdaq price.
Like General MacArthur, "I will return", but only when the AMYT Ichimoku chart turns bullish again, whenever that will be.

papillon
05/5/2021
17:07
Having listenned to the conf call earlier, it's pretty clear that there's significant overlap that will allow cost savings to be made in the combined operation. The big factor for Chiasma is presumably that Amryt will accelerate the launch of their product in the US and provide a sales organisation for ex-US thereby avoiding the need to cut a deal with partners or fund an ex-US sales team. I also assume they are somewhat cash constrained so being part of the larger entity helps with cashflow and allows increased investment in product development. There were some interesting points made about combining Myalepta with Chiasma's oral platform technology which could provide very interesting lifecycle mamagement.

Chiasma's CEO and other senior execs were on the call. I guess they will be casualties of the cost savings in due course!

whatno
05/5/2021
17:07
Competing with or bought out by...!
alphabravo321
05/5/2021
16:52
Thanks for that information, diamondstar.

There was a very informative post on the lse bb today about Chiasma and the financial impact to AMYT of today's deal. I'll copy and paste it later on.

papillon
05/5/2021
16:43
The strategy to purchase Chiasma is 100% a Joe Wiley decision. Being a Neurologist- he has been looking for Acromegaly assets from the start. I hope his instincts are right - that oral dosing with somatostatin analogue is the way forward. He will be fighting against the big boys in the acromegaly space - Amryt will be competing against Novartis Octreotide and Ipsen’s Lanreotide.
diamondstar1
05/5/2021
15:46
I was initially sceptical, having done some reading, I think the issues Chimasa has can be solved by Amryt and this could turn out to be a serious stroke...I will follow the big money and hold very tight
alphabravo321
05/5/2021
15:30
The current Nasdaq ADS price, what no, is equivalent to £1.75 per AMYT share. Unless the ADS price recovers I see the AMYT share price falling further.
papillon
05/5/2021
15:20
Looks like your call was a good one. I hope that the US analysts on today's call will be busy writing up buy notes ready for publication tomorrow!
whatno
05/5/2021
14:49
The GPM Ichimoku charts didn't lie! Glad I sold most of my shares today before Nasdaq opened.

Joe Wiley is empire building. Today's deal is good news for Chiasma shareholders, but not for AMYT holders. Not in the short term anyway. It will probably be good news for AMYT shareholders in the longer term, but I'm not interested in the longer term.

papillon
05/5/2021
12:45
I believe some yanks knew about this deal and how it would likely adversely affect the AMYT share price as the ADS price has been weak recently, especially yesterday. This weakness turned the AMYT share price and ADS Ichimoku charts strongly bearish recently.
papillon
05/5/2021
12:32
The Nasdaq pre market price of the ADS's is well down on yesterday's closing price so I've sold most of my AMYT shares.
papillon
05/5/2021
12:29
I hope I am wrong!
alphabravo321
05/5/2021
12:28
We seem to be on the wrong side of this deal
alphabravo321
05/5/2021
12:28
True - but the FDA has got tougher this year with approvals and AP101's clinical trial results were not a complete slam dunk - so there is some risk. I like the asset they are adding and especially the label expansion prospects.
whatno
05/5/2021
12:21
Dilutes the risk of AP101 but also dilutes the upside if it is approved.
dingodollars
05/5/2021
12:16
We'll see what Nasdaq thinks soon enough. I'm not expecting much.
papillon
05/5/2021
11:45
Nice acquisition. Good synergies and cost savings of $50m pa. Diversifies the portfolio and also dilutes the risk somewhat of AP101 not getting approved (although unlikely).
whatno
05/5/2021
11:02
I knew it!!
alphabravo321
04/5/2021
19:06
I dont think its a coincidence that a director bought 300,000 of these 7 weeks before q1, I am half expecting something else along with the results
alphabravo321
04/5/2021
14:09
Going by the complete lack of interest in the ADS's on Nasdaq I'm not expecting much to happen to the share price tomorrow.
papillon
04/5/2021
11:48
looking forward to noon tomorrow - expecting to be surprised to the upside
moorsie2
03/5/2021
20:37
I sincerely hope you're correct, bazworth. I have a larger holding in GPM and believe (hope!) that it will perform spectacularly well this year. I'm very bullish on the prospects for precious metals.
papillon
Chat Pages: Latest  271  270  269  268  267  266  265  264  263  262  261  260  Older

Your Recent History

Delayed Upgrade Clock